Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Enanta Pharmaceuticals, Inc. (ENTA)
USD13.23
+0.12 (+0.89%)
US NASDAQ Healthcare Biotechnology
Address
500 Arsenal Street 2472
Watertown, MA, US
Watertown, MA, US
CEO
Jay R. Luly
Website
enanta.com
IPO
2013-03-21
CIK 1177648 ISIN US29251M1062
Description
Enanta Pharmaceuticals, Inc. is a biotechnology firm dedicated to discovering and advancing small molecule therapies designed to combat a range of viral infections and various liver conditions. Its research and development efforts are primarily focused on addressing pathogens such as respiratory syncytial virus (RSV), SARS-CoV-2, human metapneumovirus (hMPV), and the hepatitis B virus (HBV). The company also holds a strategic partnership and licensing agreement with Abbott Laboratories. This collaboration involves the joint identification, development, and market introduction of specific HCV NS3 and NS3/4A protease inhibitor compounds, including known agents like paritaprevir and glecaprevir, which are utilized in the management of chronic hepatitis C virus. Founded in 1995, Enanta Pharmaceuticals, Inc. operates from its principal office located in Watertown, Massachusetts.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD13.23
+0.12 (+0.89%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
202.3K
Beta
0.99
Float Shares
20.20M
Free Float %
87.0%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -6.02% | -5.03% | +2.98% | +4.99% | +21.79% | -7.86% | +161.80% | -42.64% | -70.89% | -39.26% | -15.42% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (19 ratings, all time)
Buy
Price Targets & DCF
Current price
13.23
Low
20.00
+51.2%
Consensus
48.20
+264.4%
Median
54.00
+308.3%
High
87.00
+557.8%
Ratings Trend (MoM)
83% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 4 | 0 |
| Hold | 1 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | — | — |
| Last Quarter | — | — |
| Last Year | 2 |
22.00
+66.3%
|
| All Time | 5 |
48.20
+264.4%
|
Quality scores
Altman Z-Score
1.14
Distress
Piotroski F-Score
3 / 9
Average
MOAT Score
2 / 10
No MOAT
Composite Rating
C-
Overall Score
1 / 5
Low
DCF Score
1 / 5
Low
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
2 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
2 / 5
Medium
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%-3.4% Q1'26: +15.0% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%+29.9% ★ Q1'26: +70.8% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%-64.3% Q1'26: -69.0% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%-116.1% Q1'26: +0.0% (vs Q1'25)
-
ROIC Biotechnology: -16.1%-98.7% Q1'26: +0.0% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+0.9% ★ Q1'26: +35.3% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-2.84× Q1'26: -0.59× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Sep 2013 actual |
Sep 2014 actual |
Sep 2015 actual |
Sep 2016 actual |
Sep 2017 actual |
Sep 2018 actual |
Sep 2019 actual |
Sep 2020 actual |
Sep 2021 actual |
Sep 2022 actual |
Sep 2023 actual |
Sep 2024 actual |
Sep 2025 actual |
Sep 2026 5 Rev. Ana. 5 EPS Ana. |
Sep 2027 5 Rev. Ana. 5 EPS Ana. |
Sep 2028 4 Rev. Ana. 4 EPS Ana. |
Sep 2029 2 Rev. Ana. 1 EPS Ana. |
Sep 2030 2 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
32.05M
est: 10.08M (+218.1%)
|
47.74M
est: 178.23M (-73.2%)
|
160.88M
est: 162.89M (-1.2%)
|
88.27M
est: 88.83M (-0.6%)
|
102.81M
est: 100.72M (+2.1%)
|
206.63M
est: 208.44M (-0.9%)
|
205.20M
est: 209.85M (-2.2%)
|
122.47M
est: 124.41M (-1.6%)
|
97.07M
est: 99.90M (-2.8%)
|
86.16M
est: 89.04M (-3.2%)
|
79.20M
est: 72.88M (+8.7%)
|
67.64M
est: 71.21M (-5.0%)
|
65.32M
est: 66.16M (-1.3%)
|
68.29M
66.21M – 71.17M
+3.2% YoY
|
65.65M
60.19M – 73.47M
-3.9% YoY
|
68.91M
65.27M – 72.54M
+5.0% YoY
|
72.86M
65.04M – 79.96M
+5.7% YoY
|
121.29M
108.27M – 133.11M
+66.5% YoY
|
| EBITDA |
9.25M
est: -31.69M (+129.2%)
|
19.34M
est: 91.53M (-78.9%)
|
124.79M
est: 91.67M (+36.1%)
|
32.50M
est: -5.96M (+645.5%)
|
26.75M
est: 56.58M (-52.7%)
|
90.85M
est: 106.46M (-14.7%)
|
40.00M
est: 38.05M (+5.1%)
|
-38.00M
est: -57.25M (+33.6%)
|
-104.25M
est: -115.19M (+9.5%)
|
-119.22M
est: -112.79M (-5.7%)
|
-123.48M
est: -72.88M (-69.4%)
|
-104.51M
est: -71.21M (-46.8%)
|
-70.78M
est: -66.16M (-7.0%)
|
-68.29M
-71.17M – -66.21M
-3.2% YoY
|
-65.65M
-73.47M – -60.19M
+3.9% YoY
|
-68.91M
-72.54M – -65.27M
-5.0% YoY
|
-72.86M
-79.96M – -65.04M
-5.7% YoY
|
-121.29M
-133.11M – -108.27M
-66.5% YoY
|
| EBIT |
9.66M
est: -33.74M (+128.6%)
|
18.99M
est: 90.40M (-79.0%)
|
124.15M
est: 89.55M (+38.6%)
|
30.84M
est: -11.44M (+369.6%)
|
24.61M
est: 50.84M (-51.6%)
|
88.33M
est: 98.37M (-10.2%)
|
36.74M
est: 15.49M (+137.2%)
|
-41.64M
est: -70.25M (+40.7%)
|
-107.58M
est: -120.21M (+10.5%)
|
-122.19M
est: -118.56M (-3.1%)
|
-125.85M
est: -72.88M (-72.7%)
|
-106.85M
est: -71.21M (-50.0%)
|
-75.87M
est: -66.16M (-14.7%)
|
-68.29M
-71.17M – -66.21M
-3.2% YoY
|
-65.65M
-73.47M – -60.19M
+3.9% YoY
|
-68.91M
-72.54M – -65.27M
-5.0% YoY
|
-72.86M
-79.96M – -65.04M
-5.7% YoY
|
-121.29M
-133.11M – -108.27M
-66.5% YoY
|
| Net Income |
9.63M
est: -32.20M (+129.9%)
|
34.44M
est: 67.88M (-49.3%)
|
78.99M
est: 61.87M (+27.7%)
|
21.67M
est: -11.22M (+293.2%)
|
17.71M
est: 38.12M (-53.5%)
|
71.96M
est: 83.98M (-14.3%)
|
46.38M
est: 43.63M (+6.3%)
|
-36.17M
est: -51.25M (+29.4%)
|
-79.00M
est: -92.73M (+14.8%)
|
-121.76M
est: -107.33M (-13.4%)
|
-133.82M
est: -131.74M (-1.6%)
|
-116.05M
est: -111.07M (-4.5%)
|
-81.89M
est: -80.49M (-1.7%)
|
-55.52M
-60.75M – -32.35M
+31.0% YoY
|
-41.27M
-50.56M – -31.97M
+25.7% YoY
|
-61.07M
-77.29M – -26.08M
-48.0% YoY
|
-30.44M
-34.29M – -26.19M
+50.2% YoY
|
4.80M
4.13M – 5.41M
+115.8% YoY
|
| SGA |
6.18M
est: 6.16M (+0.3%)
|
10.02M
est: 21.89M (-54.2%)
|
13.54M
est: 14.76M (-8.3%)
|
16.97M
est: 26.30M (-35.5%)
|
20.75M
est: 24.71M (-16.0%)
|
23.44M
est: 24.02M (-2.4%)
|
26.25M
est: 44.78M (-41.4%)
|
27.36M
est: 31.21M (-12.3%)
|
32.54M
est: 32.11M (+1.3%)
|
45.48M
est: 37.05M (+22.8%)
|
52.89M
est: 44.58M (+18.6%)
|
57.85M
est: 43.56M (+32.8%)
|
43.93M
est: 40.47M (+8.5%)
|
41.78M
40.50M – 43.54M
+3.2% YoY
|
40.16M
36.82M – 44.95M
-3.9% YoY
|
42.15M
39.93M – 44.38M
+5.0% YoY
|
44.57M
39.79M – 48.91M
+5.7% YoY
|
74.20M
66.23M – 81.42M
+66.5% YoY
|
| EPS |
-0.67
est: -2.50 (+73.2%)
|
1.88
est: 6.45 (-70.8%)
|
4.23
est: 3.96 (+7.0%)
|
1.14
est: 1.08 (+5.6%)
|
0.93
est: 0.83 (+12.2%)
|
3.48
est: 3.36 (+3.6%)
|
2.37
est: 2.32 (+2.2%)
|
-1.81
est: -1.24 (-46.3%)
|
-3.92
est: -3.86 (-1.6%)
|
-5.91
est: -5.86 (-0.8%)
|
-6.38
est: -6.25 (-2.1%)
|
-5.48
est: -5.28 (-3.8%)
|
-3.84
est: -3.77 (-1.8%)
|
-2.29
-2.85 – -1.52
+39.2% YoY
|
-1.85
-2.37 – -1.50
+19.1% YoY
|
-1.92
-3.62 – -1.22
-3.7% YoY
|
-1.43
-1.61 – -1.23
+25.8% YoY
|
0.23
0.19 – 0.25
+115.8% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-11 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-08 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-07 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-06 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-05 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-04 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-01 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-30 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-29 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-28 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-27 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-24 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-23 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-22 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-21 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-20 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-17 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-16 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-18.33M
OE per share TTM
-0.86
Owner's Yield
-4.10%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
34.3%
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
43
Total invested
42.01M
Insider transactions (90d)
0
Beneficial owners (>5%)
36
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | (1) BlackRock, Inc. | 3.75M | 18.00% | 3.66M | — | 3.75M | — | HC | Delaware | 2023-01-31 | ↗ |
| 2 | (1)Names of reporting persons. BlackRock, Inc. | 3.41M | 17.00% | 3.32M | — | 3.41M | — | HC | Delaware | 2021-01-25 | ↗ |
| 3 | Armistice Capital, LLC | 2.08M | 9.99% | — | 2.08M | — | — | IA, OO | Delaware | 2023-02-14 | ↗ |
| 4 | Steven Boyd | 2.08M | 9.99% | — | 2.08M | — | — | HC, IN | United States of America | 2023-02-14 | ↗ |
| 5 | Andrew J. M. Spokes | 1.57M | 7.70% | — | 1.57M | — | — | IN | United Kingdom | 2022-02-11 | ↗ |
| 6 | David T. Kim | 1.57M | 7.70% | — | 1.57M | — | — | IN | United States | 2022-02-11 | ↗ |
| 7 | John R. Warren | 1.57M | 7.70% | — | 1.57M | — | — | IN | United States | 2022-02-11 | ↗ |
| 8 | Mark C. Wehrly | 1.57M | 7.70% | — | 1.57M | — | — | IN | United States | 2022-02-11 | ↗ |
| 9 | Michael B. Fisch | 1.57M | 7.70% | — | 1.57M | — | — | IN | United States | 2022-02-11 | ↗ |
| 10 | Michael G. Linn | 1.57M | 7.70% | — | 1.57M | — | — | IN | United States | 2022-02-11 | ↗ |
| 11 | Nicolas Giauque | 1.57M | 7.70% | — | 1.57M | — | — | IN | France | 2022-02-11 | ↗ |
| 12 | Philip D. Dreyfuss | 1.57M | 7.70% | — | 1.57M | — | — | IN | United States | 2022-02-11 | ↗ |
| 13 | Rajiv A. Patel | 1.57M | 7.70% | — | 1.57M | — | — | IN | United States | 2022-02-11 | ↗ |
| 14 | Richard B. Fried | 1.57M | 7.70% | — | 1.57M | — | — | IN | United States | 2022-02-11 | ↗ |
| 15 | Thomas G. Roberts, Jr. | 1.57M | 7.70% | — | 1.57M | — | — | IN | United States | 2022-02-11 | ↗ |
| 16 | Varun N. Gehani | 1.57M | 7.70% | — | 1.57M | — | — | IN | United States | 2022-02-11 | ↗ |
| 17 | William Seybold | 1.57M | 7.70% | — | 1.57M | — | — | IN | United States | 2022-02-11 | ↗ |
| 18 | Farallon Partners, L.L.C. | 1.48M | 7.30% | — | 1.48M | — | — | OO | Delaware | 2022-02-11 | ↗ |
| 19 | Israel A. Englander | 1.31M | 6.20% | — | 1.31M | — | 1.31M | IN | Delaware | 2024-01-11 | ↗ |
| 20 | Millennium Group Management LLC | 1.31M | 6.20% | — | 1.31M | — | 1.31M | OO | Delaware | 2024-01-11 | ↗ |
| 21 | Millennium Management LLC | 1.31M | 6.20% | — | 1.31M | — | 1.31M | OO | Delaware | 2024-01-11 | ↗ |
| 22 | STATE STREET CORPORATION | 1.13M | 5.55% | — | 1.09M | — | 1.13M | HC | — | 2022-02-11 | ↗ |
| 23 | First Manhattan Co. | 1.11M | 5.46% | 1.10M | 4.4K | 1.10M | — | BD, IA | New York | 2022-02-15 | ↗ |
| 24 | 52-0556948 | 961.4K | 4.70% | 163.5K | — | 961.4K | — | IA | Maryland | 2021-02-16 | ↗ |
| 25 | 13-3127734 | 714.4K | 3.48% | 684.9K | — | 714.4K | — | HC | Delaware | 2022-02-10 | ↗ |
| 26 | 26-0385758 | 714.4K | 3.48% | 684.9K | — | 714.4K | — | IA | Delaware | 2022-02-10 | ↗ |
| 27 | Farallon Capital Offshore Investors II, L.P. | 621.3K | 3.10% | — | 621.3K | — | — | PN | Cayman Islands | 2022-02-11 | ↗ |
| 28 | Farallon Capital Institutional Partners, L.P. | 377.1K | 1.90% | — | 377.1K | — | — | PN | California | 2022-02-11 | ↗ |
| 29 | Farallon Capital Partners, L.P. | 287.0K | 1.40% | — | 287.0K | — | — | PN | California | 2022-02-11 | ↗ |
| 30 | Farallon Capital F5 Master I, L.P. | 90.7K | 0.40% | — | 90.7K | — | — | PN | Cayman Islands | 2022-02-11 | ↗ |
| 31 | Farallon F5 (GP), L.L.C. | 90.7K | 0.40% | — | 90.7K | — | — | OO | Delaware | 2022-02-11 | ↗ |
| 32 | Farallon Capital Institutional Partners II, L.P. | 70.3K | 0.30% | — | 70.3K | — | — | PN | California | 2022-02-11 | ↗ |
| 33 | Farallon Institutional (GP) V, L.L.C. | 56.1K | 0.30% | — | 56.1K | — | — | OO | Delaware | 2022-02-11 | ↗ |
| 34 | Four Crossings Institutional Partners V, L.P. | 56.1K | 0.30% | — | 56.1K | — | — | PN | Delaware | 2022-02-11 | ↗ |
| 35 | Farallon Capital Institutional Partners III, L.P. | 45.5K | 0.20% | — | 45.5K | — | — | PN | Delaware | 2022-02-11 | ↗ |
| 36 | Farallon Capital (AM) Investors, L.P. | 25.8K | 0.10% | — | 25.8K | — | — | PN | Delaware | 2022-02-11 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
43
-88 vs prev Q
New positions
12
Closed positions
98
Increased
21
Reduced
8
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | — | 389.7K +389.7K (+100.0%) | 6.15B +6.1B (+100.0%) | 1.36% +1.356 pp | 2.03% +2.031 pp | USD15.77 +0.0% | 1 qtrs NEW |
| 2 | JANUS HENDERSON GROUP PLC | 3.73M +1.8M (+91.6%) | 58.76M +35.5M (+152.4%) | 12.97% +3.843 pp | 0.03% +0.016 pp | USD13.17 +19.7% | 3 qtrs — |
| 3 | BLACKROCK, INC. | 3.08M +1.2M (+67.8%) | 48.51M +26.6M (+121.1%) | 10.70% +2.104 pp | 0.00% +0.000 pp | USD12.36 +27.6% | 6 qtrs — |
| 4 | FARALLON CAPITAL MANAGEMENT LLC | 2.77M +650.0K (+30.6%) | 43.72M +18.3M (+72.1%) | 9.64% -0.310 pp | 0.21% +0.102 pp | USD41.38 -61.9% | 34 qtrs — |
| 5 | KRENSAVAGE ASSET MANAGEMENT, LLC | 2.77M +651.9K (+30.8%) | 43.63M +18.3M (+72.4%) | 9.62% -0.294 pp | 15.41% +4.625 pp | USD19.15 -17.7% | 44 qtrs — |
| 6 | VANGUARD GROUP INC | 2.30M +363.0K (+18.7%) | 36.30M +13.1M (+56.4%) | 8.01% -1.086 pp | 0.00% +0.000 pp | USD43.93 -64.1% | 51 qtrs — |
| 7 | DEEP TRACK CAPITAL, LP | 1.96M +2.0M (+100.0%) | 30.86M +30.9M (+100.0%) | 6.81% +6.807 pp | 0.55% +0.550 pp | USD15.77 +0.0% | 1 qtrs NEW |
| 8 | ACADIAN ASSET MANAGEMENT LLC | 885.1K +18.1K (+2.1%) | 13.95M +3.6M (+34.4%) | 3.08% -0.988 pp | 0.02% +0.005 pp | USD11.80 +33.6% | 11 qtrs — |
| 9 | MILLENNIUM MANAGEMENT LLC | 670.4K -277.7K (-29.3%) | 10.57M -775.9K (-6.8%) | 2.33% -2.114 pp | 0.00% 0.000 pp | USD11.21 +40.7% | 39 qtrs — |
| 10 | GEODE CAPITAL MANAGEMENT, LLC | 645.8K +152.6K (+30.9%) | 10.19M +4.3M (+72.5%) | 2.25% -0.067 pp | 0.00% +0.000 pp | USD37.65 -58.1% | 51 qtrs — |
| 11 | RENAISSANCE TECHNOLOGIES LLC | 642.2K +162.6K (+33.9%) | 10.13M +4.4M (+76.4%) | 2.23% -0.015 pp | 0.02% +0.008 pp | USD30.78 -48.8% | 40 qtrs — |
| 12 | STATE STREET CORP | 523.7K +51.7K (+11.0%) | 8.26M +2.6M (+46.2%) | 1.82% -0.392 pp | 0.00% +0.000 pp | USD39.63 -60.2% | 50 qtrs — |
| 13 | POINT72 ASSET MANAGEMENT, L.P. | 438.9K +138.9K (+46.3%) | 6.92M +3.3M (+92.8%) | 1.53% +0.120 pp | 0.01% +0.002 pp | USD13.17 +19.7% | 2 qtrs — |
| 14 | HILLSDALE INVESTMENT MANAGEMENT INC. | 422.3K +422.3K (+100.0%) | 6.66M +6.7M (+100.0%) | 1.98% +1.975 pp | 0.18% +0.184 pp | USD15.77 +0.0% | 1 qtrs NEW |
| 15 | MARSHALL WACE, LLP | 385.3K +109.9K (+39.9%) | 6.08M +2.8M (+84.3%) | 1.34% +0.049 pp | 0.01% +0.002 pp | USD15.93 -1.0% | 10 qtrs — |
| 16 | MORGAN STANLEY | 339.9K +57.3K (+20.3%) | 5.36M +2.0M (+58.4%) | 1.18% -0.143 pp | 0.00% +0.000 pp | USD15.67 +0.6% | 51 qtrs — |
| 17 | TWO SIGMA INVESTMENTS, LP | 285.4K +224.7K (+370.1%) | 4.50M +3.8M (+519.3%) | 0.99% +0.708 pp | 0.01% +0.005 pp | USD14.62 +7.9% | 38 qtrs — |
| 18 | INVESCO LTD. | 253.8K +194.1K (+325.2%) | 4.00M +3.3M (+460.1%) | 0.88% +0.603 pp | 0.00% +0.001 pp | USD17.30 -8.8% | 48 qtrs — |
| 19 | AQR CAPITAL MANAGEMENT LLC | 234.8K +8.0K (+3.5%) | 3.70M +988.0K (+36.4%) | 0.82% -0.247 pp | 0.00% +0.000 pp | USD6.78 +132.6% | 47 qtrs — |
| 20 | NORTHERN TRUST CORP | 229.9K +34.0K (+17.4%) | 3.63M +1.3M (+54.6%) | 0.80% -0.119 pp | 0.00% +0.000 pp | USD44.30 -64.4% | 51 qtrs — |
| 21 | GOLDMAN SACHS GROUP INC | 218.8K +52.4K (+31.5%) | 3.45M +1.5M (+73.2%) | 0.76% -0.019 pp | 0.00% +0.000 pp | USD21.38 -26.2% | 51 qtrs — |
| 22 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 218.6K +52.1K (+31.3%) | 3.45M +1.5M (+73.0%) | 0.76% -0.021 pp | 0.00% +0.000 pp | USD39.15 -59.7% | 50 qtrs — |
| 23 | DIMENSIONAL FUND ADVISORS LP | 211.6K -58.5K (-21.6%) | 3.34M +101.9K (+3.1%) | 0.74% -0.531 pp | 0.00% +0.000 pp | USD21.81 -27.7% | 44 qtrs — |
| 24 | D. E. SHAW & CO., INC. | 167.7K -58.0K (-25.7%) | 2.64M -57.3K (-2.1%) | 0.58% -0.475 pp | 0.00% 0.000 pp | USD11.25 +40.2% | 38 qtrs — |
| 25 | TWO SIGMA ADVISERS, LP | 143.3K +18.2K (+14.5%) | 2.26M +762.4K (+50.9%) | 0.50% -0.088 pp | 0.00% +0.001 pp | USD14.75 +6.9% | 34 qtrs — |
| 26 | JPMORGAN CHASE & CO | 113.0K -10.9K (-8.8%) | 1.78M +299.4K (+20.2%) | 0.53% -0.052 pp | 0.00% +0.000 pp | USD30.74 -48.7% | 40 qtrs — |
| 27 | CONNOR, CLARK & LUNN INVESTMENT MANAGEMENT LTD. | 103.9K +26.4K (+34.1%) | 1.64M +710.8K (+76.6%) | 0.36% -0.002 pp | 0.00% +0.001 pp | USD12.30 +28.2% | 9 qtrs — |
| 28 | STONEPINE CAPITAL MANAGEMENT, LLC | 100.0K -205.0K (-67.2%) | 1.58M -2.1M (-56.8%) | 0.35% -1.083 pp | 1.15% -1.817 pp | USD5.69 +177.2% | 5 qtrs — |
| 29 | BNP PARIBAS ARBITRAGE, SNC | 99.9K +80.1K (+404.0%) | 1.58M +1.3M (+563.9%) | 0.35% +0.255 pp | 0.00% +0.001 pp | USD15.89 -0.8% | 47 qtrs — |
| 30 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 99.4K +71.2K (+252.5%) | 1.57M +1.2M (+364.4%) | 0.35% +0.214 pp | 0.00% +0.000 pp | USD14.69 +7.4% | 2 qtrs — |
| 31 | SEI INVESTMENTS CO | 98.8K +24.9K (+33.8%) | 1.56M +673.8K (+76.2%) | 0.34% -0.003 pp | 0.00% +0.001 pp | USD11.68 +35.0% | 10 qtrs — |
| 32 | CITADEL ADVISORS LLC | 93.2K +93.2K (+100.0%) | 1.47M +1.5M (+100.0%) | 0.32% +0.324 pp | 0.00% +0.000 pp | USD15.77 +0.0% | 36 qtrs — |
| 33 | NUVEEN, LLC | 86.1K -78.7K (-47.8%) | 1.36M -615.1K (-31.2%) | 0.30% -0.473 pp | 0.00% 0.000 pp | USD10.21 +54.5% | 4 qtrs — |
| 34 | OPALEYE MANAGEMENT INC. | 75.0K +75.0K (+100.0%) | 1.18M +1.2M (+100.0%) | 0.26% +0.261 pp | 0.16% +0.156 pp | USD15.77 +0.0% | 1 qtrs NEW |
| 35 | BANK OF NEW YORK MELLON CORP | 72.6K +12.1K (+20.0%) | 1.14M +420.6K (+58.1%) | 0.25% -0.031 pp | 0.00% +0.000 pp | USD38.06 -58.6% | 51 qtrs — |
| 36 | PDT PARTNERS, LLC | 69.2K -16.8K (-19.6%) | 1.09M +61.6K (+6.0%) | 0.24% -0.163 pp | 0.07% +0.006 pp | USD8.61 +83.2% | 11 qtrs — |
| 37 | PANAGORA ASSET MANAGEMENT INC | 67.0K +67.0K (+100.0%) | 1.06M +1.1M (+100.0%) | 0.23% +0.233 pp | 0.00% +0.004 pp | USD15.77 +0.0% | 1 qtrs NEW |
| 38 | BANK OF AMERICA CORP /DE/ | 66.0K +36.0K (+120.3%) | 1.04M +681.9K (+190.2%) | 0.23% +0.089 pp | 0.00% +0.000 pp | USD11.64 +35.5% | 51 qtrs — |
| 39 | SQUAREPOINT OPS LLC | 66.0K +66.0K (+100.0%) | 1.04M +1.0M (+100.0%) | 0.23% +0.230 pp | 0.00% +0.001 pp | USD15.77 +0.0% | 1 qtrs NEW |
| 40 | DIADEMA PARTNERS LP | 65.1K +65.1K (+100.0%) | 1.03M +1.0M (+100.0%) | 0.23% +0.227 pp | 0.18% +0.177 pp | USD15.77 +0.0% | 1 qtrs NEW |
| 41 | WELLINGTON MANAGEMENT GROUP LLP | 63.2K +63.2K (+100.0%) | 997.0K +997.0K (+100.0%) | 0.22% +0.220 pp | 0.00% +0.000 pp | USD15.77 +0.0% | 1 qtrs NEW |
| 42 | BARCLAYS PLC | 55.0K +27.6K (+100.4%) | 867.2K +582.9K (+205.1%) | 0.19% +0.063 pp | 0.00% +0.000 pp | USD12.64 +24.8% | 51 qtrs — |
| 43 | CAMPBELL & CO INVESTMENT ADVISER LLC | 54.1K +35.3K (+187.2%) | 853.9K +628.2K (+278.4%) | 0.19% +0.100 pp | 0.04% +0.024 pp | USD14.45 +9.1% | 2 qtrs — |
| 44 | ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | 52.7K +52.7K (+100.0%) | 831.5K +831.5K (+100.0%) | 0.18% +0.183 pp | 0.00% +0.001 pp | USD15.77 +0.0% | 1 qtrs NEW |
| 45 | SUSQUEHANNA FUNDAMENTAL INVESTMENTS, LLC | 50.4K +— (+0.0%) | 795.3K +191.6K (+31.7%) | 0.18% -0.061 pp | 0.03% +0.004 pp | USD5.57 +183.1% | 5 qtrs — |
| 46 | ASSENAGON ASSET MANAGEMENT S.A. | 45.9K -8.4K (-15.4%) | 723.5K +74.0K (+11.4%) | 0.21% -0.040 pp | 0.00% +0.000 pp | USD13.40 +17.7% | 19 qtrs — |
| 47 | MAN GROUP PLC | 43.8K +3.7K (+9.2%) | 691.5K +210.8K (+43.9%) | 0.15% -0.036 pp | 0.00% +0.000 pp | USD12.29 +28.3% | 2 qtrs — |
| 48 | ADAR1 CAPITAL MANAGEMENT, LLC | 41.4K +41.4K (+100.0%) | 652.2K +652.2K (+100.0%) | 0.14% +0.144 pp | 0.05% +0.048 pp | USD15.77 +0.0% | 1 qtrs NEW |
| 49 | EAM INVESTORS, LLC | 41.0K +41.0K (+100.0%) | 645.8K +645.8K (+100.0%) | 0.14% +0.143 pp | 0.07% +0.072 pp | USD15.77 +0.0% | 1 qtrs NEW |
| 50 | PRUDENTIAL FINANCIAL INC | 40.0K +40.0K (+100.0%) | 631.0K +631.0K (+100.0%) | 0.14% +0.139 pp | 0.00% +0.001 pp | USD15.77 +0.0% | 1 qtrs NEW |
| 51 | SIO CAPITAL MANAGEMENT, LLC | 40.0K +40.0K (+100.0%) | 630.8K +630.8K (+100.0%) | 0.14% +0.139 pp | 0.10% +0.099 pp | USD15.77 +0.0% | 8 qtrs — |
| 52 | BANK OF MONTREAL /CAN/ | 37.5K +3.6K (+10.7%) | 591.1K +185.7K (+45.8%) | 0.13% -0.029 pp | 0.00% +0.000 pp | USD7.12 +121.5% | 5 qtrs — |
| 53 | IEQ CAPITAL, LLC | 36.4K -1.3K (-3.5%) | 573.8K +122.7K (+27.2%) | 0.13% -0.050 pp | 0.00% +0.000 pp | USD5.52 +185.7% | 4 qtrs — |
| 54 | AMERICAN CENTURY COMPANIES INC | 33.8K -14.8K (-30.5%) | 532.5K -48.9K (-8.4%) | 0.12% -0.110 pp | 0.00% +0.000 pp | USD11.50 +37.1% | 9 qtrs — |
| 55 | ALLIANCEBERNSTEIN L.P. | 33.7K +— (+0.0%) | 532.1K +128.2K (+31.7%) | 0.12% -0.041 pp | 0.00% +0.000 pp | USD40.61 -61.2% | 51 qtrs — |
| 56 | QUANTINNO CAPITAL MANAGEMENT LP | 33.5K -3.6K (-9.8%) | 528.2K +83.8K (+18.9%) | 0.12% -0.058 pp | 0.00% 0.000 pp | USD9.90 +59.3% | 4 qtrs — |
| 57 | STATE OF WYOMING | 32.9K +32.9K (+100.0%) | 518.6K +518.6K (+100.0%) | 0.11% +0.114 pp | 0.06% +0.057 pp | USD15.77 +0.0% | 1 qtrs NEW |
| 58 | FRANKLIN RESOURCES INC | 32.7K +32.7K (+100.0%) | 516.0K +516.0K (+100.0%) | 0.11% +0.114 pp | 0.00% +0.000 pp | USD15.77 +0.0% | 1 qtrs NEW |
| 59 | QUBE RESEARCH & TECHNOLOGIES LTD | 32.4K +20.5K (+171.7%) | 510.8K +368.1K (+258.0%) | 0.11% +0.057 pp | 0.00% +0.000 pp | USD14.09 +11.9% | 17 qtrs — |
| 60 | WELLS FARGO & COMPANY/MN | 30.7K +15.1K (+96.9%) | 484.4K +297.7K (+159.4%) | 0.11% +0.034 pp | 0.00% +0.000 pp | USD14.56 +8.3% | 50 qtrs — |
| 61 | HUDSON BAY CAPITAL MANAGEMENT LP | 30.0K +30.0K (+100.0%) | 473.1K +473.1K (+100.0%) | 0.10% +0.104 pp | 0.00% +0.002 pp | USD15.77 +0.0% | 1 qtrs NEW |
| 62 | BRIDGEWAY CAPITAL MANAGEMENT, LLC | 29.7K +— (+0.0%) | 468.4K +112.9K (+31.7%) | 0.10% -0.036 pp | 0.01% +0.002 pp | USD9.42 +67.4% | 6 qtrs — |
| 63 | RHUMBLINE ADVISERS | 28.8K -2.1K (-6.7%) | 454.9K +85.0K (+23.0%) | 0.10% -0.045 pp | 0.00% +0.000 pp | USD42.12 -62.6% | 47 qtrs — |
| 64 | THRIVENT FINANCIAL FOR LUTHERANS | 28.4K -5.7K (-16.6%) | 448.0K +41.0K (+10.1%) | 0.13% -0.027 pp | 0.00% +0.000 pp | USD5.64 +179.6% | 5 qtrs — |
| 65 | PORTLAND GLOBAL ADVISORS LLC | 24.3K +— (+0.0%) | 382.8K +92.2K (+31.7%) | 0.08% -0.029 pp | 0.04% +0.009 pp | USD47.50 -66.8% | 18 qtrs — |
| 66 | DEUTSCHE BANK AG\ | 24.1K +1.1K (+4.6%) | 380.2K +104.2K (+37.8%) | 0.11% +0.005 pp | 0.00% +0.000 pp | USD12.14 +29.9% | 2 qtrs — |
| 67 | HEADLANDS TECHNOLOGIES LLC | 22.6K +22.6K (+100.0%) | 356.3K +356.3K (+100.0%) | 0.08% +0.079 pp | 0.03% +0.030 pp | USD15.77 +0.0% | 1 qtrs NEW |
| 68 | CWM, LLC | 20.7K +19.0 (+0.1%) | 326.0K +79.0K (+32.0%) | 0.07% -0.025 pp | 0.00% +0.000 pp | USD6.06 +160.2% | 17 qtrs — |
| 69 | STATE OF WISCONSIN INVESTMENT BOARD | 18.6K +18.6K (+100.0%) | 293.4K +293.4K (+100.0%) | 0.06% +0.065 pp | 0.00% +0.001 pp | USD15.77 +0.0% | 1 qtrs NEW |
| 70 | PERSISTENT ASSET PARTNERS LTD | 17.5K +17.5K (+100.0%) | 275.4K +275.4K (+100.0%) | 0.06% +0.061 pp | 0.12% +0.124 pp | USD15.77 +0.0% | 1 qtrs NEW |
| 71 | PRICE T ROWE ASSOCIATES INC /MD/ | 14.4K +4.3K (+42.0%) | 228.0K +106.0K (+86.9%) | 0.05% +0.003 pp | 0.00% +0.000 pp | USD13.09 +20.5% | 2 qtrs — |
| 72 | METLIFE INVESTMENT MANAGEMENT, LLC | 14.4K +7.8K (+119.7%) | 227.2K +148.7K (+189.4%) | 0.05% +0.019 pp | 0.00% +0.001 pp | USD11.10 +42.1% | 33 qtrs — |
| 73 | QUEST PARTNERS LLC | 14.2K +4.0K (+39.0%) | 223.6K +101.5K (+83.2%) | 0.05% +0.002 pp | 0.01% +0.005 pp | USD12.33 +27.9% | 9 qtrs — |
| 74 | VIRTU FINANCIAL LLC | 14.0K +14.0K (+100.0%) | 220.0K +220.0K (+100.0%) | 0.05% +0.049 pp | 0.01% +0.009 pp | USD15.77 +0.0% | 3 qtrs — |
| 75 | JUMP FINANCIAL, LLC | 13.9K +13.9K (+100.0%) | 219.2K +219.2K (+100.0%) | 0.05% +0.048 pp | 0.00% +0.003 pp | USD15.77 +0.0% | 1 qtrs NEW |
| 76 | MIRAE ASSET GLOBAL ETFS HOLDINGS LTD. | 12.7K +3.0K (+30.5%) | 199.8K +83.6K (+72.0%) | 0.04% -0.002 pp | 0.00% +0.000 pp | USD12.98 +21.5% | 7 qtrs — |
| 77 | JAIN GLOBAL LLC | 12.5K +12.5K (+100.0%) | 197.8K +197.8K (+100.0%) | 0.04% +0.044 pp | 0.00% +0.001 pp | USD15.77 +0.0% | 1 qtrs NEW |
| 78 | RUSSELL INVESTMENTS GROUP, LTD. | 11.5K -5.0K (-30.2%) | 182.4K -14.5K (-7.3%) | 0.04% -0.037 pp | 0.00% +0.000 pp | USD56.02 -71.8% | 37 qtrs — |
| 79 | KINGSVIEW WEALTH MANAGEMENT, LLC | 10.7K +10.7K (+100.0%) | 168.0K +168.0K (+100.0%) | 0.04% +0.037 pp | 0.00% +0.002 pp | USD15.77 +0.0% | 1 qtrs NEW |
| 80 | FOX RUN MANAGEMENT, L.L.C. | 10.2K +10.2K (+100.0%) | 160.6K +160.6K (+100.0%) | 0.04% +0.035 pp | 0.02% +0.025 pp | USD15.77 +0.0% | 1 qtrs NEW |
| 81 | WEALTH ENHANCEMENT ADVISORY SERVICES, LLC | 10.7K +74.0 (+0.7%) | 145.6K +27.6K (+23.4%) | 0.05% +0.000 pp | 0.00% +0.000 pp | USD7.62 +107.0% | 3 qtrs — |
| 82 | CANADA PENSION PLAN INVESTMENT BOARD | 8.9K +8.9K (+100.0%) | 140.4K +140.4K (+100.0%) | 0.03% +0.031 pp | 0.00% +0.000 pp | USD15.77 +0.0% | 1 qtrs NEW |
| 83 | POLICE & FIREMEN'S RETIREMENT SYSTEM OF NEW JERSEY | 6.7K +— (+0.0%) | 105.3K +25.4K (+31.7%) | 0.02% -0.008 pp | 0.00% +0.000 pp | USD8.09 +94.9% | 5 qtrs — |
| 84 | NEW YORK STATE COMMON RETIREMENT FUND | 6.1K -1.7K (-21.9%) | 95.7K +2.7K (+2.9%) | 0.02% -0.015 pp | 0.00% +0.000 pp | USD49.08 -67.9% | 47 qtrs — |
| 85 | UBS GROUP AG | 5.1K -10.2K (-66.7%) | 80.3K -102.9K (-56.2%) | 0.02% -0.054 pp | 0.00% +0.000 pp | USD10.60 +48.8% | 45 qtrs — |
| 86 | CLEARSTEAD TRUST, LLC | 5.1K +— (+0.0%) | 79.9K +19.2K (+31.7%) | 0.02% -0.006 pp | 0.01% +0.002 pp | USD51.87 -69.6% | 14 qtrs — |
| 87 | CHINA UNIVERSAL ASSET MANAGEMENT CO., LTD. | 4.7K -4.0K (-46.2%) | 74.2K -30.5K (-29.2%) | 0.02% -0.019 pp | 0.01% -0.003 pp | USD8.92 +76.8% | 5 qtrs — |
| 88 | FMR LLC | 4.3K +2.5K (+141.6%) | 68.0K +46.6K (+218.3%) | 0.02% +0.007 pp | 0.00% +0.000 pp | USD20.92 -24.6% | 19 qtrs — |
| 89 | MIRAE ASSET GLOBAL INVESTMENTS CO., LTD. | 3.6K +2.8K (+333.9%) | 56.5K +46.6K (+471.7%) | 0.02% +0.013 pp | 0.00% +0.000 pp | USD13.52 +16.6% | 5 qtrs — |
| 90 | STRS OHIO | 3.2K +3.2K (+100.0%) | 50.5K +50.5K (+100.0%) | 0.02% +0.015 pp | 0.00% +0.000 pp | USD15.77 +0.0% | 1 qtrs NEW |
| 91 | PINNACLE WEALTH PLANNING SERVICES, INC. | 2.5K +2.5K (+100.0%) | 39.9K +39.9K (+100.0%) | 0.01% +0.009 pp | 0.00% +0.004 pp | USD15.77 +0.0% | 1 qtrs NEW |
| 92 | LEGAL & GENERAL GROUP PLC | 2.4K +734.0 (+43.1%) | 38.4K +18.1K (+88.7%) | 0.01% +0.001 pp | 0.00% +0.000 pp | USD38.90 -59.5% | 46 qtrs — |
| 93 | MEEDER ASSET MANAGEMENT INC | 2.0K +2.0K (+100.0%) | 31.9K +31.9K (+100.0%) | 0.01% +0.007 pp | 0.00% +0.002 pp | USD15.77 +0.0% | 1 qtrs NEW |
| 94 | AMERITAS INVESTMENT PARTNERS, INC. | 2.0K +— (+0.0%) | 31.1K +7.5K (+31.7%) | 0.01% -0.002 pp | 0.00% +0.000 pp | USD33.83 -53.4% | 36 qtrs — |
| 95 | CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | 1.7K +423.0 (+33.7%) | 26.5K +11.4K (+76.1%) | 0.01% 0.000 pp | 0.00% +0.000 pp | USD12.93 +22.0% | 51 qtrs — |
| 96 | STERLING CAPITAL MANAGEMENT LLC | 1.6K +181.0 (+13.0%) | 24.8K +8.1K (+48.9%) | 0.01% -0.001 pp | 0.00% +0.000 pp | USD10.58 +49.1% | 6 qtrs — |
| 97 | VERSANT CAPITAL MANAGEMENT, INC | 1.4K +— (+0.0%) | 22.5K +5.4K (+31.7%) | 0.01% +0.000 pp | 0.00% +0.001 pp | USD7.56 +108.6% | 3 qtrs — |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
Held by 71 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Invesco NASDAQ Future Gen 200 ETF QQQS | 0.52% | 114.2K | 0.20% |
| 2 | ALPS Medical Breakthroughs ETF SBIO | 0.20% | 435.0K | 0.50% |
| 3 | iShares Micro-Cap ETF IWC | 0.09% | 1.31M | 0.60% |
| 4 | Vanguard U.S. Momentum Factor ETF VFMO | 0.07% | 1.19M | 0.13% |
| 5 | Vanguard Global Momentum Factor ETF VMO.TO | 0.06% | 220.3K | 0.38% |
| 6 | Innovator U.S. Small Cap Managed Floor ETF RFLR | 0.04% | 35.5K | 0.89% |
| 7 | iShares Nasdaq US Biotechnology UCITS ETF BTEE.L | 0.03% | 21.9K | 0.35% |
| 8 | iShares Nasdaq US Biotechnology UCITS ETF BTEC.L | 0.03% | 327.5K | 0.35% |
| 9 | iShares Biotechnology ETF IBB | 0.03% | 2.72M | 0.44% |
| 10 | Invesco NASDAQ Biotech UCITS ETF SBIO.L | 0.03% | 126.7K | 0.40% |
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
3.00
Bullish
Ratio by volume
3.00
Bullish
Buys
18
Sells
6
Shares acquired
172.4K
Shares disposed
21.4K
Cash buys
—
Cash sales
—
Net activity
+150,970
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-03-11 | Vance Terry | Director | A-Award | A | Stock Option (right to buy) | 20,000 | 14.17 | 283.4K | 20,000 | D | ↗ |
| 2026-03-11 | Russell Lesley | Director | A-Award | A | Stock Option (right to buy) | 20,000 | 14.17 | 283.4K | 20,000 | D | ↗ |
| 2026-03-11 | Peterson Kristine | Director | A-Award | A | Stock Option (right to buy) | 20,000 | 14.17 | 283.4K | 20,000 | D | ↗ |
| 2026-03-11 | Hata Yujiro S | Director | A-Award | A | Stock Option (right to buy) | 20,000 | 14.17 | 283.4K | 20,000 | D | ↗ |
| 2026-03-11 | FOLETTA MARK G | Director | A-Award | A | Stock Option (right to buy) | 20,000 | 14.17 | 283.4K | 20,000 | D | ↗ |
| 2026-03-11 | CARTER BRUCE L A | Director | A-Award | A | Stock Option (right to buy) | 20,000 | 14.17 | 283.4K | 20,000 | D | ↗ |
| 2026-02-12 | Rottinghaus Scott T. | Officer | A-Award | A | Common Stock | 5,225 | 0.00 | — | 28,667 | D | ↗ |
| 2026-02-12 | Or Yat Sun | Officer | A-Award | A | Common Stock | 1,650 | 0.00 | — | 373,042 | D | ↗ |
| 2026-02-12 | Luu Brendan | Officer | A-Award | A | Common Stock | 1,575 | 0.00 | — | 39,904 | D | ↗ |
| 2026-02-12 | Luly Jay R. | Director / Officer | A-Award | A | Common Stock | 4,800 | 0.00 | — | 862,826 | D | ↗ |
| 2026-02-12 | Kowalsky Matthew Paul | Officer | A-Award | A | Common Stock | 1,318 | 0.00 | — | 1,318 | D | ↗ |
| 2026-02-12 | Kieffer Tara Lynn | Officer | A-Award | A | Common Stock | 4,987 | 0.00 | — | 37,182 | D | ↗ |
| 2025-12-05 | Trout Harry R. III | Officer | S-Sale | D | Common Stock | 542 | 14.23 | 7.7K | 16,348 | D | ↗ |
| 2025-12-05 | Rottinghaus Scott T. | Officer | S-Sale | D | Common Stock | 798 | 14.23 | 11.4K | 21,792 | D | ↗ |
| 2025-12-05 | Or Yat Sun | Officer | S-Sale | D | Common Stock | 2,390 | 14.23 | 34.0K | 371,392 | D | ↗ |
| 2025-12-05 | Luu Brendan | Officer | S-Sale | D | Common Stock | 1,394 | 14.23 | 19.8K | 38,329 | D | ↗ |
| 2025-12-05 | Luly Jay R. | Director / Officer | S-Sale | D | Common Stock | 4,743 | 14.23 | 67.5K | 858,026 | D | ↗ |
| 2025-12-05 | Kieffer Tara Lynn | Officer | S-Sale | D | Common Stock | 2,106 | 14.23 | 30.0K | 30,620 | D | ↗ |
| 2025-12-05 | Capps Kathleen S. | Officer | S-Sale | D | Common Stock | 323 | 14.23 | 4.6K | 8,377 | D | ↗ |
| 2025-12-02 | Trout Harry R. III | Officer | S-Sale | D | Common Stock | 380 | 13.96 | 5.3K | 16,890 | D | ↗ |
| 2025-12-02 | Capps Kathleen S. | Officer | S-Sale | D | Common Stock | 207 | 13.96 | 2.9K | 8,700 | D | ↗ |
| 2025-12-01 | Trout Harry R. III | Officer | F-InKind | D | Common Stock | 105 | 14.12 | 1.5K | 17,270 | D | ↗ |
| 2025-12-01 | Or Yat Sun | Officer | F-InKind | D | Common Stock | 753 | 14.12 | 10.6K | 373,782 | D | ↗ |
| 2025-12-01 | Luu Brendan | Officer | F-InKind | D | Common Stock | 498 | 14.12 | 7.0K | 39,723 | D | ↗ |
| 2025-12-01 | Luly Jay R. | Director / Officer | F-InKind | D | Common Stock | 1,885 | 14.12 | 26.6K | 862,769 | D | ↗ |
| 2025-12-01 | Kieffer Tara Lynn | Officer | F-InKind | D | Common Stock | 753 | 14.12 | 10.6K | 32,726 | D | ↗ |
| 2025-12-01 | Capps Kathleen S. | Officer | F-InKind | D | Common Stock | 85 | 14.12 | 1.2K | 8,907 | D | ↗ |
| 2025-11-25 | Trout Harry R. III | Officer | A-Award | A | Stock Option (right to buy) | 12,925 | 13.66 | 176.6K | 12,925 | D | ↗ |
| 2025-11-25 | Rottinghaus Scott T. | Officer | A-Award | A | Stock Option (right to buy) | 110,000 | 13.66 | 1.50M | 110,000 | D | ↗ |
| 2025-11-25 | Or Yat Sun | Officer | A-Award | A | Stock Option (right to buy) | 110,000 | 13.66 | 1.50M | 110,000 | D | ↗ |
| 2025-11-25 | Luu Brendan | Officer | A-Award | A | Stock Option (right to buy) | 90,000 | 13.66 | 1.23M | 90,000 | D | ↗ |
| 2025-11-25 | Luly Jay R. | Director / Officer | A-Award | A | Stock Option (right to buy) | 310,000 | 13.66 | 4.23M | 310,000 | D | ↗ |
| 2025-11-25 | Kowalsky Matthew Paul | Officer | A-Award | A | Stock Option (right to buy) | 90,000 | 13.66 | 1.23M | 90,000 | D | ↗ |
| 2025-11-25 | Kieffer Tara Lynn | Officer | A-Award | A | Stock Option (right to buy) | 100,000 | 13.66 | 1.37M | 100,000 | D | ↗ |
| 2025-11-25 | Capps Kathleen S. | Officer | A-Award | A | Stock Option (right to buy) | 6,325 | 13.66 | 86.4K | 6,325 | D | ↗ |
| 2025-08-26 | Trout Harry R. III | Officer | — | — | Stock Option (right to buy) | 10,000 | 63.35 | 633.5K | 0 | D | ↗ |
| 2025-08-26 | Capps Kathleen S. | Officer | — | — | Stock Option (right to buy) | 2,668 | 30.00 | 80.0K | 0 | D | ↗ |
| 2025-08-08 | Rottinghaus Scott T. | Officer | F-InKind | D | Common Stock | 2,217 | 6.99 | 15.5K | 22,590 | D | ↗ |
| 2025-03-13 | Vance Terry | Director | A-Award | A | Stock Option (right to buy) | 15,700 | 6.83 | 107.2K | 15,700 | D | ↗ |
| 2025-03-13 | Russell Lesley | Director | A-Award | A | Stock Option (right to buy) | 15,700 | 6.83 | 107.2K | 15,700 | D | ↗ |
| 2025-03-13 | Peterson Kristine | Director | A-Award | A | Stock Option (right to buy) | 15,700 | 6.83 | 107.2K | 15,700 | D | ↗ |
| 2025-03-13 | Hata Yujiro S | Director | A-Award | A | Stock Option (right to buy) | 15,700 | 6.83 | 107.2K | 15,700 | D | ↗ |
| 2025-03-13 | FOLETTA MARK G | Director | A-Award | A | Stock Option (right to buy) | 15,700 | 6.83 | 107.2K | 15,700 | D | ↗ |
| 2025-03-13 | CARTER BRUCE L A | Director | A-Award | A | Stock Option (right to buy) | 15,700 | 6.83 | 107.2K | 15,700 | D | ↗ |
| 2025-02-12 | Rottinghaus Scott T. | Officer | F-InKind | D | Common Stock | 2,861 | 5.59 | 16.0K | 24,807 | D | ↗ |
| 2025-02-12 | Or Yat Sun | Officer | A-Award | A | Common Stock | 9,750 | 0.00 | — | 378,859 | D | ↗ |
| 2025-02-12 | MELLETT PAUL J | Officer | F-InKind | D | Common Stock | 3,326 | 5.59 | 18.6K | 95,884 | D | ↗ |
| 2025-02-12 | Luu Brendan | Officer | F-InKind | D | Common Stock | 3,326 | 5.59 | 18.6K | 40,221 | D | ↗ |
| 2025-02-12 | Luly Jay R. | Director / Officer | P-Purchase | A | Common Stock | 45,000 | 5.69 | 256.1K | 846,638 | D | ↗ |
| 2025-02-12 | Kieffer Tara Lynn | Officer | A-Award | A | Common Stock | 7,500 | 0.00 | — | 36,805 | D | ↗ |
| 2024-12-06 | Rottinghaus Scott T. | Officer | S-Sale | D | Common Stock | 866 | 8.06 | 7.0K | 17,918 | D | ↗ |
| 2024-12-06 | Or Yat Sun | Officer | S-Sale | D | Common Stock | 2,591 | 8.06 | 20.9K | 369,109 | D | ↗ |
| 2024-12-06 | MELLETT PAUL J | Officer | S-Sale | D | Common Stock | 2,591 | 8.06 | 20.9K | 91,710 | D | ↗ |
| 2024-12-06 | Luu Brendan | Officer | S-Sale | D | Common Stock | 2,283 | 8.06 | 18.4K | 36,047 | D | ↗ |
| 2024-12-06 | Luly Jay R. | Director / Officer | S-Sale | D | Common Stock | 5,142 | 8.06 | 41.4K | 801,638 | D | ↗ |
| 2024-12-06 | Kieffer Tara Lynn | Officer | S-Sale | D | Common Stock | 2,283 | 8.06 | 18.4K | 29,305 | D | ↗ |
| 2024-12-01 | Or Yat Sun | Officer | F-InKind | D | Common Stock | 1,595 | 8.60 | 13.7K | 371,700 | D | ↗ |
| 2024-12-01 | MELLETT PAUL J | Officer | F-InKind | D | Common Stock | 1,595 | 8.60 | 13.7K | 94,301 | D | ↗ |
| 2024-12-01 | Luu Brendan | Officer | F-InKind | D | Common Stock | 753 | 8.60 | 6.5K | 38,330 | D | ↗ |
| 2024-12-01 | Luly Jay R. | Director / Officer | F-InKind | D | Common Stock | 3,829 | 8.60 | 32.9K | 806,780 | D | ↗ |
| 2024-12-01 | Kieffer Tara Lynn | Officer | F-InKind | D | Common Stock | 753 | 8.60 | 6.5K | 31,588 | D | ↗ |
| 2024-11-27 | Rottinghaus Scott T. | Officer | A-Award | A | Stock Option (right to buy) | 87,000 | 8.83 | 768.2K | 87,000 | D | ↗ |
| 2024-11-27 | Or Yat Sun | Officer | A-Award | A | Stock Option (right to buy) | 87,000 | 8.83 | 768.2K | 87,000 | D | ↗ |
| 2024-11-27 | MELLETT PAUL J | Officer | A-Award | A | Stock Option (right to buy) | 81,000 | 8.83 | 715.2K | 81,000 | D | ↗ |
| 2024-11-27 | Luu Brendan | Officer | A-Award | A | Stock Option (right to buy) | 75,000 | 8.83 | 662.3K | 75,000 | D | ↗ |
| 2024-11-27 | Luly Jay R. | Director / Officer | A-Award | A | Stock Option (right to buy) | 250,000 | 8.83 | 2.21M | 250,000 | D | ↗ |
| 2024-11-27 | Kowalsky Matthew Paul | Officer | A-Award | A | Stock Option (right to buy) | 75,000 | 8.83 | 662.3K | 75,000 | D | ↗ |
| 2024-11-27 | Kieffer Tara Lynn | Officer | A-Award | A | Stock Option (right to buy) | 81,000 | 8.83 | 715.2K | 81,000 | D | ↗ |
| 2024-08-08 | Rottinghaus Scott T. | Officer | F-InKind | D | Common Stock | 1,466 | 12.73 | 18.7K | 18,784 | — | ↗ |
| 2024-07-15 | Rottinghaus Scott T. | Officer | S-Sale | D | Common Stock | 5,375 | 17.08 | 91.8K | 21,717 | — | ↗ |
| 2024-07-12 | Rottinghaus Scott T. | Officer | S-Sale | D | Common Stock | 2,271 | 15.04 | 34.2K | 21,717 | — | ↗ |
| 2024-07-11 | Rottinghaus Scott T. | Officer | S-Sale | D | Common Stock | 4,299 | 15.07 | 64.8K | 23,988 | — | ↗ |
| 2024-06-17 | Kieffer Tara Lynn | Officer | S-Sale | D | Common Stock | 7,266 | 12.33 | 89.6K | 32,341 | — | ↗ |
| 2024-04-29 | Kowalsky Matthew Paul | Officer | A-Award | A | Stock Option (right to buy) | 150,000 | 13.25 | 1.99M | 150,000 | — | ↗ |
| 2024-03-06 | Vance Terry | Director | A-Award | A | Stock Option (right to buy) | 15,700 | 15.66 | 245.9K | 15,700 | — | ↗ |
| 2024-03-06 | Russell Lesley | Director | A-Award | A | Stock Option (right to buy) | 15,700 | 15.66 | 245.9K | 15,700 | — | ↗ |
| 2024-03-06 | Peterson Kristine | Director | A-Award | A | Stock Option (right to buy) | 15,700 | 15.66 | 245.9K | 15,700 | — | ↗ |
| 2024-03-06 | Hata Yujiro S | Director | A-Award | A | Stock Option (right to buy) | 15,700 | 15.66 | 245.9K | 15,700 | — | ↗ |
| 2024-03-06 | FOLETTA MARK G | Director | A-Award | A | Stock Option (right to buy) | 15,700 | 15.66 | 245.9K | 15,700 | — | ↗ |
| 2024-03-06 | CARTER BRUCE L A | Director | A-Award | A | Stock Option (right to buy) | 15,700 | 15.66 | 245.9K | 15,700 | — | ↗ |
| 2024-02-26 | Gardiner Nathaniel S. | Officer | M-Exempt | D | Stock Option (Right to Buy) | 5,187 | 8.99 | 46.6K | 77,813 | — | ↗ |
| 2024-02-12 | Rottinghaus Scott T. | Officer | A-Award | A | Common Stock | 2,576 | 0.00 | — | 29,042 | — | ↗ |
| 2024-02-12 | Or Yat Sun | Officer | A-Award | A | Common Stock | 3,680 | 0.00 | — | 374,375 | — | ↗ |
| 2024-02-12 | MELLETT PAUL J | Officer | A-Award | A | Common Stock | 3,320 | 0.00 | — | 96,869 | — | ↗ |
| 2024-02-12 | Luu Brendan | Officer | F-InKind | D | Common Stock | 973 | 12.41 | 12.1K | 39,083 | — | ↗ |
| 2024-02-12 | Luly Jay R. | Director / Officer | F-InKind | D | Common Stock | 1,584 | 12.41 | 19.7K | 810,609 | — | ↗ |
| 2024-02-12 | Kieffer Tara Lynn | Officer | A-Award | A | Common Stock | 3,320 | 0.00 | — | 40,580 | — | ↗ |
| 2024-02-12 | Gardiner Nathaniel S. | Officer | F-InKind | D | Common Stock | 973 | 12.41 | 12.1K | 70,501 | — | ↗ |
| 2023-12-13 | Vance Terry | Director | S-Sale | D | Common Stock | 15,295 | 9.12 | 139.5K | 5,800 | — | ↗ |
| 2023-12-05 | Rottinghaus Scott T. | Officer | S-Sale | D | Common Stock | 534 | 9.63 | 5.1K | 26,466 | — | ↗ |
| 2023-12-05 | Or Yat Sun | Officer | S-Sale | D | Common Stock | 2,412 | 9.63 | 23.2K | 370,695 | — | ↗ |
| 2023-12-05 | MELLETT PAUL J | Officer | S-Sale | D | Common Stock | 2,412 | 9.63 | 23.2K | 93,549 | — | ↗ |
| 2023-12-05 | Luu Brendan | Officer | S-Sale | D | Common Stock | 2,125 | 9.63 | 20.5K | 36,736 | — | ↗ |
| 2023-12-05 | Luly Jay R. | Director / Officer | S-Sale | D | Common Stock | 7,230 | 9.63 | 69.6K | 806,793 | — | ↗ |
| 2023-12-05 | Kieffer Tara Lynn | Officer | S-Sale | D | Common Stock | 2,125 | 9.63 | 20.5K | 37,260 | — | ↗ |
| 2023-12-05 | Gardiner Nathaniel S. | Officer | S-Sale | D | Common Stock | 2,412 | 9.63 | 23.2K | 68,154 | — | ↗ |
| 2023-12-01 | Or Yat Sun | Officer | F-InKind | D | Common Stock | 1,595 | 9.49 | 15.1K | 373,107 | — | ↗ |
| 2023-12-01 | MELLETT PAUL J | Officer | F-InKind | D | Common Stock | 1,595 | 9.49 | 15.1K | 95,961 | — | ↗ |
| 2023-12-01 | Luu Brendan | Officer | F-InKind | D | Common Stock | 753 | 9.49 | 7.1K | 38,861 | — | ↗ |
| 2023-12-01 | Luly Jay R. | Director / Officer | F-InKind | D | Common Stock | 5,787 | 9.49 | 54.9K | 814,023 | — | ↗ |
| 2023-12-01 | Kieffer Tara Lynn | Officer | F-InKind | D | Common Stock | 753 | 9.49 | 7.1K | 39,385 | — | ↗ |
| 2023-12-01 | Gardiner Nathaniel S. | Officer | F-InKind | D | Common Stock | 1,595 | 9.49 | 15.1K | 70,566 | — | ↗ |
| 2023-11-22 | Rottinghaus Scott T. | Officer | A-Award | A | Stock Option (right to buy) | 86,000 | 8.99 | 773.1K | 86,000 | — | ↗ |
| 2023-11-22 | Or Yat Sun | Officer | A-Award | A | Stock Option (right to buy) | 86,000 | 8.99 | 773.1K | 86,000 | — | ↗ |
| 2023-11-22 | MELLETT PAUL J | Officer | A-Award | A | Stock Option (right to buy) | 83,000 | 8.99 | 746.2K | 83,000 | — | ↗ |
| 2023-11-22 | Luu Brendan | Officer | A-Award | A | Stock Option (right to buy) | 83,000 | 8.99 | 746.2K | 83,000 | — | ↗ |
| 2023-11-22 | Luly Jay R. | Director / Officer | A-Award | A | Stock Option (right to buy) | 264,000 | 8.99 | 2.37M | 264,000 | — | ↗ |
| 2023-11-22 | Kieffer Tara Lynn | Officer | A-Award | A | Stock Option (right to buy) | 83,000 | 8.99 | 746.2K | 83,000 | — | ↗ |
| 2023-11-22 | Gardiner Nathaniel S. | Officer | A-Award | A | Stock Option (right to buy) | 83,000 | 8.99 | 746.2K | 83,000 | — | ↗ |
| 2023-08-08 | Rottinghaus Scott T. | Officer | F-InKind | D | Common Stock | 1,467 | 17.23 | 25.3K | 25,533 | — | ↗ |
| 2023-04-18 | Gardiner Nathaniel S. | Officer | M-Exempt | A | Common Stock | 6,667 | 30.00 | 200.0K | 79,980 | — | ↗ |
| 2023-03-16 | Vance Terry | Director | M-Exempt | D | Stock Option (right to buy) | 5,800 | 14.00 | 81.2K | 0 | — | ↗ |
| 2023-03-15 | Or Yat Sun | Officer | M-Exempt | D | Stock Option (Right to Buy) | 13,925 | 14.00 | 195.0K | 0 | — | ↗ |
| 2023-03-15 | MELLETT PAUL J | Officer | M-Exempt | A | Common Stock | 10,440 | 14.00 | 146.2K | 107,996 | — | ↗ |
| 2023-03-13 | Luly Jay R. | Director / Officer | M-Exempt | A | Common Stock | 27,912 | 14.00 | 390.8K | 847,722 | — | ↗ |
| 2023-03-02 | Vance Terry | Director | A-Award | A | Stock Option (right to buy) | 10,800 | 47.72 | 515.4K | 10,800 | — | ↗ |
| 2023-03-02 | Russell Lesley | Director | A-Award | A | Stock Option (right to buy) | 10,800 | 47.72 | 515.4K | 10,800 | — | ↗ |
| 2023-03-02 | Peterson Kristine | Director | A-Award | A | Stock Option (right to buy) | 10,800 | 47.72 | 515.4K | 10,800 | — | ↗ |
| 2023-03-02 | Hata Yujiro S | Director | A-Award | A | Stock Option (right to buy) | 10,800 | 47.72 | 515.4K | 10,800 | — | ↗ |
| 2023-03-02 | FOLETTA MARK G | Director | A-Award | A | Stock Option (right to buy) | 10,800 | 47.72 | 515.4K | 10,800 | — | ↗ |
| 2023-03-02 | CARTER BRUCE L A | Director | A-Award | A | Stock Option (right to buy) | 10,800 | 47.72 | 515.4K | 10,800 | — | ↗ |
| 2023-02-13 | Or Yat Sun | Officer | F-InKind | D | Common Stock | 7,752 | 52.77 | 409.1K | 374,702 | — | ↗ |
| 2023-02-13 | MELLETT PAUL J | Officer | A-Award | A | Common Stock | 9,250 | 0.00 | — | 92,713 | — | ↗ |
| 2023-02-13 | Luu Brendan | Officer | A-Award | A | Common Stock | 8,945 | 0.00 | — | 34,670 | — | ↗ |
| 2023-02-13 | Luly Jay R. | Director / Officer | A-Award | A | Common Stock | 15,285 | 0.00 | — | 803,590 | — | ↗ |
| 2023-02-13 | Kieffer Tara Lynn | Officer | A-Award | A | Common Stock | 9,250 | 0.00 | — | 35,116 | — | ↗ |
| 2023-02-13 | Gardiner Nathaniel S. | Officer | A-Award | A | Common Stock | 9,250 | 0.00 | — | 68,301 | — | ↗ |
| 2023-02-09 | MELLETT PAUL J | Officer | S-Sale | D | Common Stock | 4,200 | 53.64 | 225.3K | 84,263 | — | ↗ |
| 2023-01-09 | MELLETT PAUL J | Officer | M-Exempt | A | Common Stock | 2,812 | 14.18 | 39.9K | 88,463 | — | ↗ |
| 2022-12-19 | MELLETT PAUL J | Officer | M-Exempt | A | Common Stock | 4,148 | 14.18 | 58.8K | 85,651 | — | ↗ |
| 2022-12-19 | Luly Jay R. | Officer | M-Exempt | A | Common Stock | 14,500 | 27.58 | 399.9K | 788,305 | — | ↗ |
| 2022-12-16 | Luly Jay R. | Officer | M-Exempt | A | Common Stock | 13,851 | 14.00 | 193.9K | 803,805 | — | ↗ |
| 2022-12-01 | Or Yat Sun | Officer | F-InKind | D | Common Stock | 1,055 | 44.33 | 46.8K | 359,187 | — | ↗ |
| 2022-12-01 | MELLETT PAUL J | Officer | F-InKind | D | Common Stock | 1,055 | 44.33 | 46.8K | 81,503 | — | ↗ |
| 2022-12-01 | Luu Brendan | Officer | F-InKind | D | Common Stock | 498 | 44.33 | 22.1K | 25,725 | — | ↗ |
| 2022-12-01 | Luly Jay R. | Officer | F-InKind | D | Common Stock | 5,659 | 44.33 | 250.9K | 773,805 | — | ↗ |
| 2022-12-01 | Kieffer Tara Lynn | Officer | F-InKind | D | Common Stock | 498 | 44.33 | 22.1K | 25,866 | — | ↗ |
| 2022-12-01 | Gardiner Nathaniel S. | Officer | F-InKind | D | Common Stock | 1,055 | 44.33 | 46.8K | 59,051 | — | ↗ |
| 2022-11-23 | Rottinghaus Scott T. | Officer | A-Award | A | Common Stock | 7,000 | 0.00 | — | 27,000 | — | ↗ |
| 2022-11-23 | Or Yat Sun | Officer | A-Award | A | Stock Option (right to buy) | 45,000 | 0.00 | — | 45,000 | — | ↗ |
| 2022-11-23 | MELLETT PAUL J | Officer | A-Award | A | Stock Option (right to buy) | 45,000 | 0.00 | — | 45,000 | — | ↗ |
| 2022-11-23 | Luu Brendan | Officer | A-Award | A | Common Stock | 18,500 | 0.00 | — | 26,223 | — | ↗ |
| 2022-11-23 | Luly Jay R. | Officer | A-Award | A | Stock Option (right to buy) | 134,000 | 0.00 | — | 134,000 | — | ↗ |
| 2022-11-23 | Kieffer Tara Lynn | Officer | A-Award | A | Common Stock | 18,500 | 0.00 | — | 26,364 | — | ↗ |
| 2022-11-23 | Gardiner Nathaniel S. | Officer | A-Award | A | Stock Option (right to buy) | 45,000 | 0.00 | — | 45,000 | — | ↗ |
| 2022-08-08 | Rottinghaus Scott T. | Officer | A-Award | A | Common Stock | 20,000 | 0.00 | — | 20,000 | — | ↗ |
| 2022-06-17 | MELLETT PAUL J | Officer | M-Exempt | D | Stock Option (right to buy) | 3,480 | 0.00 | — | 0 | — | ↗ |
| 2022-04-04 | Adda Nathalie | Officer | S-Sale | D | Common Stock | 2,500 | 70.56 | 176.4K | 65,267 | — | ↗ |
| 2022-04-01 | Adda Nathalie | Officer | M-Exempt | D | Stock Option (Right to Buy) | 2,895 | 48.52 | 140.5K | 6,285 | — | ↗ |
| 2022-03-21 | CARTER BRUCE L A | Director | M-Exempt | A | Common Stock | 6,000 | 25.58 | 153.5K | 6,000 | — | ↗ |
| 2022-03-03 | Vance Terry | Director | A-Award | A | Stock Option (right to buy) | 7,500 | 0.00 | — | 7,500 | — | ↗ |
| 2022-03-03 | Russell Lesley | Director | A-Award | A | Stock Option (right to buy) | 7,500 | 0.00 | — | 7,500 | — | ↗ |
| 2022-03-03 | Peterson Kristine | Director | A-Award | A | Stock Option (right to buy) | 7,500 | 68.22 | 511.7K | 7,500 | — | ↗ |
| 2022-03-03 | Hata Yujiro S | Director | A-Award | A | Stock Option (right to buy) | 7,500 | 0.00 | — | 7,500 | — | ↗ |
| 2022-03-03 | FOLETTA MARK G | Director | A-Award | A | Stock Option (right to buy) | 7,500 | 0.00 | — | 7,500 | — | ↗ |
| 2022-03-03 | CARTER BRUCE L A | Director | A-Award | A | Stock Option (right to buy) | 7,500 | 0.00 | — | 7,500 | — | ↗ |
| 2022-03-02 | Adda Nathalie | Officer | M-Exempt | A | Common Stock | 12,481 | 43.46 | 542.4K | 47,463 | — | ↗ |
| 2022-03-01 | Adda Nathalie | Officer | S-Sale | D | Common Stock | 24,239 | 70.26 | 1.70M | 35,082 | — | ↗ |
| 2022-02-14 | Or Yat Sun | Officer | A-Award | A | Common Stock | 615 | 0.00 | — | 337,776 | — | ↗ |
| 2022-02-14 | MELLETT PAUL J | Officer | A-Award | A | Common Stock | 615 | 0.00 | — | 56,617 | — | ↗ |
| 2022-02-14 | Luu Brendan | Officer | A-Award | A | Common Stock | 286 | 0.00 | — | 7,086 | — | ↗ |
| 2022-02-14 | Luly Jay R. | Officer | A-Award | A | Common Stock | 1,627 | 0.00 | — | 712,418 | — | ↗ |
| 2022-02-14 | Kieffer Tara Lynn | Officer | A-Award | A | Common Stock | 327 | 0.00 | — | 7,127 | — | ↗ |
| 2022-02-14 | Gardiner Nathaniel S. | Officer | F-InKind | D | Common Stock | 957 | 62.49 | 59.8K | 46,239 | — | ↗ |
| 2022-02-14 | Adda Nathalie | Officer | F-InKind | D | Common Stock | 954 | 62.49 | 59.6K | 34,982 | — | ↗ |
| 2022-01-15 | Luly Jay R. | Director / Officer | M-Exempt | A | Common Stock | 10,063 | 11.77 | 118.4K | 710,791 | — | ↗ |
| 2022-01-11 | Adda Nathalie | Officer | M-Exempt | D | Stock Option (Right to Buy) | 9,200 | 43.46 | 399.8K | 36,820 | — | ↗ |
| 2021-12-01 | Or Yat Sun | Officer | F-InKind | D | Common Stock | 557 | 87.68 | 48.8K | 337,161 | — | ↗ |
| 2021-12-01 | MELLETT PAUL J | Officer | F-InKind | D | Common Stock | 557 | 87.68 | 48.8K | 56,002 | — | ↗ |
| 2021-12-01 | Luly Jay R. | Director / Officer | F-InKind | D | Common Stock | 1,944 | 87.68 | 170.4K | 700,728 | — | ↗ |
| 2021-12-01 | Gardiner Nathaniel S. | Officer | F-InKind | D | Common Stock | 557 | 87.68 | 48.8K | 59,226 | — | ↗ |
| 2021-12-01 | Adda Nathalie | Officer | S-Sale | D | Common Stock | 1,500 | 87.60 | 131.4K | 34,902 | — | ↗ |
| 2021-11-19 | Or Yat Sun | Officer | A-Award | A | Stock Option (right to buy) | 28,400 | 75.33 | 2.14M | 28,400 | — | ↗ |
| 2021-11-19 | MELLETT PAUL J | Officer | A-Award | A | Common Stock | 6,800 | 0.00 | — | 56,559 | — | ↗ |
| 2021-11-19 | Luu Brendan | Officer | A-Award | A | Common Stock | 6,800 | 0.00 | — | 6,800 | — | ↗ |
| 2021-11-19 | Luly Jay R. | Director / Officer | A-Award | A | Stock Option (right to buy) | 107,800 | 75.33 | 8.12M | 107,800 | — | ↗ |
| 2021-11-19 | Kieffer Tara Lynn | Officer | A-Award | A | Common Stock | 6,800 | 0.00 | — | 6,800 | — | ↗ |
| 2021-11-19 | Gardiner Nathaniel S. | Officer | A-Award | A | Stock Option (right to buy) | 28,400 | 75.33 | 2.14M | 28,400 | — | ↗ |
| 2021-11-19 | Adda Nathalie | Officer | A-Award | A | Common Stock | 6,800 | 0.00 | — | 33,744 | — | ↗ |
| 2021-11-01 | Adda Nathalie | Officer | S-Sale | D | Common Stock | 7,495 | 85.02 | 637.2K | 27,044 | — | ↗ |
| 2021-10-11 | Adda Nathalie | Officer | M-Exempt | D | Stock Option (Right to Buy) | 4,047 | 43.46 | 175.9K | 54,770 | — | ↗ |
| 2021-10-08 | Adda Nathalie | Officer | M-Exempt | D | Stock Option (Right to Buy) | 13,453 | 43.46 | 584.7K | 58,817 | — | ↗ |
| 2021-09-15 | Luly Jay R. | Director / Officer | S-Sale | D | Common Stock | 4,516 | 59.06 | 266.7K | 676,972 | — | ↗ |
| 2021-08-19 | Hata Yujiro S | Director | A-Award | A | Stock Option (right to buy) | 13,144 | 48.58 | 638.5K | 13,144 | — | ↗ |
| 2021-03-02 | Vance Terry | Director | A-Award | A | Stock Option (right to buy) | 7,500 | 49.92 | 374.4K | 7,500 | — | ↗ |
| 2021-03-02 | Russell Lesley | Director | A-Award | A | Stock Option (right to buy) | 7,500 | 49.92 | 374.4K | 7,500 | — | ↗ |
| 2021-03-02 | Peterson Kristine | Director | A-Award | A | Stock Option (right to buy) | 7,500 | 49.92 | 374.4K | 7,500 | — | ↗ |
| 2021-03-02 | FOLETTA MARK G | Director | A-Award | A | Stock Option (right to buy) | 7,500 | 49.92 | 374.4K | 7,500 | — | ↗ |
| 2021-03-02 | CARTER BRUCE L A | Director | A-Award | A | Stock Option (right to buy) | 7,500 | 49.92 | 374.4K | 7,500 | — | ↗ |
| 2021-01-26 | Or Yat Sun | Officer | M-Exempt | A | Common Stock | 4,872 | 11.77 | 57.3K | 330,918 | — | ↗ |
| 2021-01-25 | Luu Brendan | Officer | A-Award | A | Stock Option (right to buy) | 75,000 | 48.03 | 3.60M | 75,000 | — | ↗ |
| 2021-01-08 | MELLETT PAUL J | Officer | S-Sale | D | Common Stock | 6,000 | 45.58 | 273.5K | 61,759 | — | ↗ |
| 2020-12-15 | Or Yat Sun | Officer | M-Exempt | D | Restricted Stock Units | 5,250 | 0.00 | — | 0 | — | ↗ |
| 2020-12-15 | MELLETT PAUL J | Officer | M-Exempt | D | Restricted Stock Units | 2,625 | 0.00 | — | 0 | — | ↗ |
| 2020-12-15 | Luly Jay R. | Director / Officer | M-Exempt | D | Restricted Stock Units | 7,500 | 0.00 | — | 0 | — | ↗ |
| 2020-12-15 | Gardiner Nathaniel S. | Officer | M-Exempt | D | Restricted Stock Units | 5,250 | 0.00 | — | 0 | — | ↗ |
| 2020-12-15 | Adda Nathalie | Officer | F-InKind | D | Common Stock | 1,540 | 42.52 | 65.5K | 26,944 | — | ↗ |
| 2020-12-07 | Kieffer Tara Lynn | Officer | A-Award | A | Stock Option (right to buy) | 65,000 | 42.62 | 2.77M | 65,000 | — | ↗ |
| 2020-12-03 | Gardiner Nathaniel S. | Officer | M-Exempt | A | Common Stock | 1,667 | 30.00 | 50.0K | 38,538 | — | ↗ |
| 2020-11-20 | Or Yat Sun | Officer | A-Award | A | Stock Option (right to buy) | 30,800 | 43.57 | 1.34M | 30,800 | — | ↗ |
Executive team
Top executives
EBIT / Employee
-579.1K
Shares Outstanding
23.22M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2025 | Jay R. Luly, Ph.D. President and Chief Executive Officer | 803.3K | — | 128.6K | 1.22M | 591.7K | 22.1K | 2.77M | 48.84% | ↗ |
| 2 | 2025 | Scott T. Rottinghaus, M.D. Chief Medical Officer | 560.3K | — | 53.6K | 425.9K | 281.3K | 22.1K | 1.34M | 35.70% | ↗ |
| 3 | 2025 | Yat Sun Or, Ph.D. Chief Scientific Officer | 553.2K | — | 53.6K | 425.9K | 239.4K | 21.8K | 1.29M | 37.06% | ↗ |
| 4 | 2024 | Jay R. Luly, Ph.D. President and Chief Executive Officer | 779.9K | — | 166.4K | 1.30M | 429.5K | 22.1K | 2.70M | 54.31% | ↗ |
| 5 | 2024 | Matthew P. Kowalsky, J.D. Chief Legal Officer | 195.3K | — | 74.3K | 1.09M | 111.8K | 1.3K | 1.47M | 79.07% | ↗ |
| 6 | 2024 | Scott T. Rottinghaus, M.D. Chief Medical Officer | 544.0K | — | 58.3K | 422.7K | 210.0K | 22.1K | 1.26M | 38.26% | ↗ |
| 7 | 2024 | Yat Sun Or, Ph.D. Chief Scientific Officer | 537.1K | — | 59.9K | 422.7K | 181.2K | 21.9K | 1.22M | 39.47% | ↗ |
| 8 | 2024 | Paul J. Mellett Chief Financial and Administrative Officer | 486.3K | — | 56.9K | 407.9K | 163.3K | 22.1K | 1.14M | 40.90% | ↗ |
| 9 | 2023 | Jay R. Luly, Ph.D. President and Chief Executive Officer | 755.4K | — | 3.52M | 3.08M | 475.9K | 20.6K | 7.86M | 84.07% | ↗ |
| 10 | 2023 | Nathaniel S. Gardiner, J.D. Chief Legal Officer and Corporate Secretary | 475.3K | — | 1.15M | 1.04M | 176.8K | 20.6K | 2.86M | 76.44% | ↗ |
| 11 | 2023 | Brendan Luu Chief Business Officer | 436.1K | — | 1.03M | 920.7K | 166.2K | 20.6K | 2.58M | 75.84% | ↗ |
| 12 | 2023 | Yat Sun Or, Ph.D. Chief Scientific Officer | 501.3K | — | 764.3K | 985.1K | 199.7K | 19.2K | 2.47M | 70.84% | ↗ |
| 13 | 2023 | Paul J. Mellett Chief Financial and Administrative Officer | 454.0K | — | 739.7K | 985.1K | 177.5K | 19.4K | 2.38M | 72.60% | ↗ |
| 14 | 2023 | Scott T. Rottinghaus, M.D. Chief Medical Officer | 530.3K | — | 577.1K | 345.3K | 190.7K | 11.4K | 1.65M | 55.74% | ↗ |
| 15 | 2022 | Jay R. Luly, Ph.D. President and Chief Executive Officer | 725.1K | — | 2.31M | 3.74M | 483.0K | 19.4K | 7.27M | 83.12% | ↗ |
| 16 | 2022 | Scott T. Rottinghaus, M.D. Senior Vice President and Chief Medical Officer | 77.6K | 62.5K | 1.60M | 2.63M | 29.3K | 337.00 | 4.40M | 96.14% | ↗ |
| 17 | 2022 | Scott T. Rottinghaus, M.D. Chief Medical Officer | 77.6K | 62.5K | 1.60M | 2.63M | 29.3K | 337.00 | 4.40M | 96.14% | ↗ |
| 18 | 2022 | Yat Sun Or, Ph.D. Senior Vice President, Research & Development and Chief Scientific Officer | 501.3K | — | 764.3K | 985.1K | 199.7K | 19.2K | 2.47M | 70.84% | ↗ |
| 19 | 2022 | Nathaniel S. Gardiner, J.D. Chief Legal Officer and Corporate Secretary | 458.1K | — | 739.7K | 985.1K | 180.5K | 19.4K | 2.38M | 72.39% | ↗ |
| 20 | 2022 | Nathaniel S. Gardiner, J.D. Senior Vice President and General Counsel | 458.1K | — | 739.7K | 985.1K | 180.5K | 19.4K | 2.38M | 72.39% | ↗ |
| 21 | 2022 | Paul J. Mellett Senior Vice President, Finance & Administration and Chief Financial Officer | 454.0K | — | 739.7K | 985.1K | 177.5K | 19.4K | 2.38M | 72.60% | ↗ |
| 22 | 2022 | Brendan Luu Chief Business Officer | 411.3K | — | 739.7K | 985.1K | 158.1K | 19.4K | 2.31M | 74.55% | ↗ |
| 23 | 2022 | Yat Sun Or, Ph.D. Chief Scientific Officer | 486.5K | — | 609.8K | 652.5K | 224.0K | 19.2K | 1.99M | 63.37% | ↗ |
| 24 | 2022 | Paul J. Mellett Chief Financial and Administrative Officer | 440.4K | — | 582.6K | 652.5K | 192.8K | 19.2K | 1.89M | 65.44% | ↗ |
| 25 | 2021 | Jay R. Luly, Ph.D. President and Chief Executive Officer | 693.2K | — | 1.78M | 2.28M | 518.8K | 19.2K | 5.29M | 76.74% | ↗ |
| 26 | 2021 | Brendan Luu Chief Business Officer | 254.8K | 75.0K | 296.2K | 1.76M | 119.8K | 1.4K | 2.50M | 82.00% | ↗ |
| 27 | 2021 | Brendan Luu Senior Vice President, Business Development | 254.8K | 75.0K | 296.2K | 1.76M | 119.8K | 1.4K | 2.50M | 82.00% | ↗ |
| 28 | 2021 | Tara L. Kieffer, Ph.D. Senior Vice President, New Product Strategy & Development | 305.1K | — | 256.2K | 1.35M | 128.3K | 2.4K | 2.04M | 78.66% | ↗ |
| 29 | 2021 | Yat Sun Or, Ph.D. Chief Scientific Officer | 486.5K | — | 609.8K | 652.5K | 224.0K | 19.2K | 1.99M | 63.37% | ↗ |
| 30 | 2021 | Yat Sun Or, Ph.D. Senior Vice President, Research & Development and Chief Scientific Officer | 486.5K | — | 609.8K | 652.5K | 224.0K | 19.2K | 1.99M | 63.37% | ↗ |
| 31 | 2021 | Yat Sun Or, Ph.D. Senior Vice President, Research & Development, Chief Scientific Officer | 486.5K | — | 609.8K | 652.5K | 224.0K | 19.2K | 1.99M | 63.37% | ↗ |
| 32 | 2021 | Nathaniel S. Gardiner, J.D. Senior Vice President and General Counsel | 444.7K | — | 582.6K | 652.5K | 198.7K | 19.2K | 1.90M | 65.09% | ↗ |
| 33 | 2021 | Nathaniel S. Gardiner, J.D. Chief Legal Officer and Corporate Secretary | 444.7K | — | 582.6K | 652.5K | 198.7K | 19.2K | 1.90M | 65.09% | ↗ |
| 34 | 2021 | Paul J. Mellett Senior Vice President, Finance & Administration and Chief Financial Officer | 440.4K | — | 582.6K | 652.5K | 192.8K | 19.2K | 1.89M | 65.44% | ↗ |
| 35 | 2021 | Paul J. Mellett Chief Financial and Administrative Officer | 440.4K | — | 582.6K | 652.5K | 192.8K | 19.2K | 1.89M | 65.44% | ↗ |
| 36 | 2021 | Paul J. Mellett Senior Vice President, Finance & Administration, Chief Financial Officer | 440.4K | — | 582.6K | 652.5K | 192.8K | 19.2K | 1.89M | 65.44% | ↗ |
| 37 | 2020 | Jay R. Luly, Ph.D. President and Chief Executive Officer | 667.1K | — | 497.0K | 3.60M | 415.7K | 19.2K | 5.20M | 78.80% | ↗ |
| 38 | 2020 | Yat Sun Or, Ph.D. Senior Vice President, Research & Development and Chief Scientific Officer | 472.1K | — | 187.8K | 981.5K | 184.2K | 19.2K | 1.84M | 63.38% | ↗ |
| 39 | 2020 | Yat Sun Or, Ph.D. Senior Vice President, Research & Development, Chief Scientific Officer | 472.1K | — | 187.8K | 981.5K | 184.2K | 19.2K | 1.84M | 63.38% | ↗ |
| 40 | 2020 | Nathalie Adda, M.D. Senior Vice President, Chief Medical Officer | 451.6K | — | 187.8K | 981.5K | 173.4K | 19.2K | 1.81M | 64.48% | ↗ |
| 41 | 2020 | Nathaniel S. Gardiner, J.D. Senior Vice President and General Counsel | 431.0K | — | 187.8K | 981.5K | 169.5K | 19.2K | 1.79M | 65.36% | ↗ |
| 42 | 2020 | Paul J. Mellett Senior Vice President, Finance & Administration and Chief Financial Officer | 425.9K | — | 187.8K | 981.5K | 167.5K | 19.2K | 1.78M | 65.62% | ↗ |
| 43 | 2020 | Paul J. Mellett Senior Vice President, Finance & Administration, Chief Financial Officer | 425.9K | — | 187.8K | 981.5K | 167.5K | 19.2K | 1.78M | 65.62% | ↗ |
| 44 | 2019 | Jay R. Luly, Ph.D. President and Chief Executive Officer | 641.8K | — | 457.6K | 3.03M | 337.3K | 19.2K | 4.48M | 77.73% | ↗ |
| 45 | 2019 | Yat Sun Or, Ph.D. Senior Vice President, Research & Development, Chief Scientific Officer | 453.9K | — | 104.3K | 890.5K | 163.0K | 19.2K | 1.63M | 61.00% | ↗ |
| 46 | 2019 | Paul J. Mellett Senior Vice President, Finance & Administration, Chief Financial Officer | 411.8K | — | 104.3K | 845.9K | 150.4K | 19.2K | 1.53M | 62.05% | ↗ |
| 47 | 2019 | Yat Sun Or, Ph.D. Senior Vice President, Research & Development and Chief Scientific Officer | 428.0K | — | 275.3K | 630.9K | 159.1K | 18.9K | 1.51M | 59.93% | ↗ |
| 48 | 2019 | Nathalie Adda, M.D. Senior Vice President, Chief Medical Officer | 421.4K | — | 275.3K | 630.9K | 148.2K | 18.9K | 1.49M | 60.63% | ↗ |
| 49 | 2019 | Paul J. Mellett Senior Vice President, Finance & Administration and Chief Financial Officer | 394.9K | — | 254.1K | 604.0K | 141.1K | 18.9K | 1.41M | 60.73% | ↗ |
| 50 | 2019 | Nathaniel S. Gardiner, J.D. Senior Vice President and General Counsel | 398.9K | — | 232.9K | 577.2K | 142.4K | 18.9K | 1.37M | 59.12% | ↗ |
| 51 | 2018 | Jay R. Luly, Ph.D. President and Chief Executive Officer | 611.2K | — | 838.5K | 2.68M | 311.2K | 18.9K | 4.46M | 78.92% | ↗ |
| 52 | 2018 | Yat Sun Or, Ph.D. Senior Vice President, Research & Development and Chief Scientific Officer | 401.0K | — | 574.4K | 599.6K | 170.0K | 18.6K | 1.76M | 66.57% | ↗ |
| 53 | 2018 | Nathalie Adda, M.D. Senior Vice President, Chief Medical Officer | 400.3K | — | 574.4K | 599.6K | 165.6K | 18.6K | 1.76M | 66.76% | ↗ |
| 54 | 2018 | Paul J. Mellett Senior Vice President, Finance & Administration and Chief Financial Officer | 370.7K | — | 557.1K | 513.9K | 147.6K | 18.6K | 1.61M | 66.61% | ↗ |
| 55 | 2018 | Nathaniel S. Gardiner, J.D. Senior Vice President and General Counsel | 368.1K | — | 545.6K | 428.3K | 149.0K | 18.6K | 1.51M | 64.51% | ↗ |
| 56 | 2017 | Jay R. Luly, Ph.D. President and Chief Executive Officer | 581.2K | — | 1.28M | 2.06M | 345.6K | 18.6K | 4.28M | 77.92% | ↗ |
| 57 | 2017 | Yat Sun Or, Ph.D. Senior Vice President, Research & Development and Chief Scientific Officer | 401.0K | — | 574.4K | 599.6K | 170.0K | 18.6K | 1.76M | 66.57% | ↗ |
| 58 | 2017 | Nathalie Adda, M.D. Senior Vice President, Chief Medical Officer | 400.3K | — | 574.4K | 599.6K | 165.6K | 18.6K | 1.76M | 66.76% | ↗ |
| 59 | 2017 | Paul J. Mellett Senior Vice President, Finance & Administration and Chief Financial Officer | 370.7K | — | 557.1K | 513.9K | 147.6K | 18.6K | 1.61M | 66.61% | ↗ |
| 60 | 2017 | Nathaniel S. Gardiner, J.D. Senior Vice President and General Counsel | 368.1K | — | 545.6K | 428.3K | 149.0K | 18.6K | 1.51M | 64.51% | ↗ |
| 61 | 2016 | Jay R. Luly, Ph.D. President and Chief Executive Officer | 542.4K | — | 405.0K | 2.18M | 291.8K | 15.9K | 3.44M | 75.27% | ↗ |
| 62 | 2016 | Yat Sun Or, Ph.D. Senior Vice President, Research & Development and Chief Scientific Officer | 386.1K | — | 122.4K | 654.8K | 151.0K | 15.9K | 1.33M | 58.43% | ↗ |
| 63 | 2016 | Paul J. Mellett Senior Vice President, Finance & Administration and Chief Financial Officer | 359.9K | — | 108.3K | 595.3K | 123.2K | 15.9K | 1.20M | 58.51% | ↗ |
| 64 | 2016 | Nathaniel S. Gardiner, J.D. Senior Vice President and General Counsel | 353.4K | — | 94.2K | 506.0K | 116.8K | 15.9K | 1.09M | 55.25% | ↗ |
| 65 | 2016 | Nathalie Adda, M.D. Senior Vice President, Chief Medical Officer | 383.4K | 52.5K | 162.1K | 317.5K | 65.6K | 15.9K | 997.0K | 48.10% | ↗ |
| 66 | 2015 | Jay R. Luly, Ph.D. President and Chief Executive Officer | 520.7K | 286.4K | 225.3K | 2.52M | — | 15.7K | 3.57M | 76.93% | ↗ |
| 67 | 2015 | Yat Sun Or, Ph.D. Senior Vice President, Research & Development and Chief Scientific Officer | 374.8K | 151.0K | 96.8K | 1.08M | — | 15.7K | 1.72M | 68.45% | ↗ |
| 68 | 2015 | Paul J. Mellett Senior Vice President, Finance & Administration and Chief Financial Officer | 344.9K | 122.5K | 86.2K | 960.2K | — | 15.7K | 1.53M | 68.41% | ↗ |
| 69 | 2014 | Jay R. Luly, Ph.D. President and Chief Executive Officer | 489.4K | 262.5K | — | 1.76M | — | 11.4K | 2.52M | 69.70% | ↗ |
| 70 | 2014 | Jay R. Luly, Ph.D. President and Chief Executive Officer | 489.4K | 262.5K | — | 1.76M | — | 11.4K | 2.52M | 69.70% | ↗ |
| 71 | 2014 | Yat Sun Or, Ph.D. Senior Vice President, Research Development and Chief Scientific Officer | 365.3K | 148.9K | — | 878.0K | — | 11.4K | 1.40M | 62.56% | ↗ |
| 72 | 2014 | Yat Sun Or, Ph.D. Senior Vice President, Research & Development and Chief Scientific Officer | 365.3K | 148.9K | — | 878.0K | — | 11.4K | 1.40M | 62.56% | ↗ |
| 73 | 2014 | Paul J. Mellett Senior Vice President, Finance & Administration and Chief Financial Officer | 322.4K | 117.9K | — | 878.0K | — | 11.4K | 1.33M | 66.03% | ↗ |
| 74 | 2014 | Paul J. Mellett Senior Vice President, Finance Administration and Chief Financial Officer | 322.4K | 117.9K | — | 878.0K | — | 11.4K | 1.33M | 66.03% | ↗ |
| 75 | 2013 | Jay R. Luly, Ph.D. President and Chief Executive Officer | 448.5K | 235.4K | — | 960.5K | — | 4.4K | 1.65M | 58.25% | ↗ |
| 76 | 2013 | Jay R. Luly, Ph.D. President and Chief Executive Officer | 448.5K | 235.4K | — | 960.5K | — | 4.4K | 1.65M | 58.25% | ↗ |
| 77 | 2013 | Yat Sun Or, Ph.D. Senior Vice President, Research & Development and Chief Scientific Officer | 343.3K | 143.2K | — | 502.0K | — | 4.4K | 992.8K | 50.56% | ↗ |
| 78 | 2013 | Yat Sun Or, Ph.D. Senior Vice President, Research Development and Chief Scientific Officer | 343.3K | 143.2K | — | 502.0K | — | 4.4K | 992.8K | 50.56% | ↗ |
| 79 | 2013 | Paul J. Mellett Senior Vice President, Finance Administration and Chief Financial Officer | 305.6K | 114.6K | — | 499.5K | — | 4.4K | 924.2K | 54.05% | ↗ |
| 80 | 2013 | Paul J. Mellett Senior Vice President, Finance & Administration and Chief Financial Officer | 305.6K | 114.6K | — | 499.5K | — | 4.4K | 924.2K | 54.05% | ↗ |
| 81 | 2012 | Jay R. Luly, Ph.D. President and Chief Executive Officer | 407.5K | 213.9K | — | 145.7K | — | 4.4K | 771.6K | 18.89% | ↗ |
| 82 | 2012 | Yat Sun Or, Ph.D. Senior Vice President, Research Development and Chief Scientific Officer | 321.4K | 136.6K | — | 143.7K | — | 4.4K | 606.1K | 23.71% | ↗ |
| 83 | 2012 | Paul J. Mellett Senior Vice President, Finance Administration and Chief Financial Officer | 284.2K | 117.3K | — | 54.7K | — | 4.4K | 460.5K | 11.87% | ↗ |
| 84 | 2011 | Jay R. Luly, Ph.D. President and Chief Executive Officer | 397.1K | 173.5K | — | 35.2K | — | 4.4K | 610.2K | 5.77% | ↗ |
| 85 | 2011 | Yat Sun Or, Ph.D. Senior Vice President, Research Development and Chief Scientific Officer | 313.2K | 105.5K | — | 80.7K | — | 4.4K | 503.8K | 16.01% | ↗ |
| 86 | 2011 | Paul J. Mellett Senior Vice President, Finance Administration and Chief Financial Officer | 276.9K | 79.5K | — | 13.2K | — | 4.4K | 374.0K | 3.53% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Scott T. Rottinghaus | Chief Medical Officer | 863.7K | — |
| Yat Sun Or | Chief Scientific Officer | 814.3K | — |
| Jay R. Luly | President, Chief Executive Officer & Director | 742.3K | — |
| Nathaniel S. Gardiner | Consultant | 672.7K | male |
| Brendan Luu | Chief Business Officer | 622.9K | male |
| Matthew Kowalsky | Chief Legal Officer & Corporate Secretary | 575.7K | male |
| Tara Lynn Kieffer | Chief Product Strategy Officer | 496.9K | female |
| Kathleen S. Capps | Executive Director of Accounting, Controller & Interim Principal Accounting Officer | — | female |
| Jennifer Viera | Executive Director of Investor Relations & Corporate Communications | — | female |
| Harry R. Trout | VP of Finance & Interim Principal Financial Officer | — | male |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
| Transaction Date | Disclosed | Representative | District | Owner | Type | Amount | Link |
|---|---|---|---|---|---|---|---|
| 2023-07-12 | 2023-08-13 | Daniel Goldman | NY10 | — | Sale | $1,001 - $15,000 | ↗ |
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for ENTA
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
